Ascendis Pharma A/S - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ASND Nasdaq 2836 ascendispharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ascendis Pharma A/S

Ascendis Pharma Gains FDA Nod For Yuviwel And New Growth Prospects - Mar 5th, 2026 5:17 am
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference - Mar 4th, 2026 8:32 pm
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia - Mar 4th, 2026 7:54 pm
This Biopharma Stock Flirts With Buy Point After New FDA Approval - Mar 4th, 2026 11:19 am
Ascendis Wins FDA Approval For Rare Disease Therapy - Mar 4th, 2026 3:45 am
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference - Mar 2nd, 2026 6:43 am
Ascendis wins FDA approval of dwarfism drug - Mar 2nd, 2026 5:22 am
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - Feb 27th, 2026 3:57 pm
Assessing Ascendis Pharma (ASND) Valuation After Strong 1 Year Return And Growing Growth Expectations - Feb 24th, 2026 7:10 pm
Ascendis (ASND) Q4 2025 Earnings Call Transcript - Feb 23rd, 2026 12:26 pm
European Equities Traded in the US as American Depositary Receipts Start Week Lower - Feb 23rd, 2026 9:02 am
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million - Feb 22nd, 2026 12:36 pm
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position - Feb 22nd, 2026 12:25 pm
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - Feb 22nd, 2026 12:16 pm
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges - Feb 22nd, 2026 11:56 am
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday trading - Feb 20th, 2026 9:11 am
Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth - Feb 20th, 2026 2:10 am
Ascendis Pharma Revenue Growth Meets Regulatory Countdown For TransCon CNP - Feb 16th, 2026 2:09 am
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor - Feb 12th, 2026 10:23 am
Ascendis Pharma Shows Steady Progress Toward Long-Term Growth, Wedbush Says - Feb 12th, 2026 9:58 am